• Explore /
  • Poster
  • / A phase II trial of CapeOX plus nivolumab for early relapsed HER2-negative gastric cancer (JACCRO GC-11: FirSTAR trial).

A phase II trial of CapeOX plus nivolumab for early relapsed HER2-negative gastric cancer (JACCRO GC-11: FirSTAR trial).

Abstract Poster

Authors

null

Hiroyuki Arai

Department of Clinical Oncology, St. Marianna University School of Medicine, Kawasaki, Japan

Hiroyuki Arai , Eisuke Inoue , Masanori Terashima , Eishi Baba , Nobuhisa Matsuhashi , Kei Muro , Toshifumi Yamaguchi , Satoshi Yuki , Wataru Ichikawa , Masashi Fujii , Yu Sunakawa

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Gastrointestinal Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session A: Cancers of the Esophagus and Stomach and Other Gastrointestinal Cancers

Track

Esophageal and Gastric Cancer,Small Bowel Cancer,Other GI Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

jRCTs031220572

Citation

J Clin Oncol 42, 2024 (suppl 3; abstr TPS423)

DOI

10.1200/JCO.2024.42.3_suppl.TPS423

Abstract #

TPS423

Poster Bd #

N8

Abstract Disclosures

Similar Posters

First Author: Ilya Tsimafeyeu

First Author: Yoshiaki Nakamura

Poster

2024 ASCO Gastrointestinal Cancers Symposium

Randomized phase II study comparing neoadjuvant FLOT versus DOS for patients with type 4 or large type 3 gastric cancer (JCOG2204).

Randomized phase II study comparing neoadjuvant FLOT versus DOS for patients with type 4 or large type 3 gastric cancer (JCOG2204).

First Author: Izuma Nakayama

First Author: Manish A. Shah